NCT07227922 Clofutriben Pharmacokinetics in Patients With Impaired Renal Function
| NCT ID | NCT07227922 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Sparrow Pharmaceuticals |
| Condition | Moderate Renal Impairment |
| Study Type | INTERVENTIONAL |
| Enrollment | 16 participants |
| Start Date | 2025-11-30 |
| Primary Completion | 2026-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 16 participants in total. It began in 2025-11-30 with a primary completion date of 2026-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a Phase 1, single-center, open-label, single-dose trial. Sixteen participants are planned: 8 participants with moderate renal impairment and 8 matched control participants with normal renal function.
Eligibility Criteria
Inclusion Criteria: * Male and female participants with stable moderate renal impairment (estimated glomerular filtration rate \[eGFR\]: 30 to \<60 mL/min) and matched (by sex, age, and weight) control participants with normal renal function (eGFR: ≥90 mL/min) will be enrolled in this trial. Exclusion Criteria: * Participant whose current or recent medical conditions, medications, or procedures could increase participant's safety risk, or whom the Investigator considers not suitable for entry into the trial or the participant, or who has clinically significant abnormal 12-lead electrocardiogram (ECG)/ vital sign measurements/ laboratory test results at Screening and Check-in, will not be enrolled
Frequently Asked Questions
Who can join the NCT07227922 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 83 Years, studying Moderate Renal Impairment. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07227922 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07227922 currently recruiting?
Yes, NCT07227922 is actively recruiting participants. Visit ClinicalTrials.gov or contact Sparrow Pharmaceuticals to inquire about joining.
Where is the NCT07227922 trial being conducted?
This trial is being conducted at Orlando, United States.
Who is sponsoring the NCT07227922 clinical trial?
NCT07227922 is sponsored by Sparrow Pharmaceuticals. The trial plans to enroll 16 participants.